Managing anti-fibrotic treatment side effects webinar

Lung Foundation Australia, in collaboration with the Centre of Research Excellence in Pulmonary Fibrosis present this webinar with Susanne Webster, Clinical Nurse Consultant in Interstitial Lung Disease (ILD).  

For people living with idiopathic pulmonary fibrosis (IPF) or pulmonary fibrosis (PF), antifibrotic medicines such as nintedanib (Ofev®) and pirfenidone (Esbriet®) may be an important part of their treatment plan. Although these medications do not reverse existing lung scarring, studies suggest they can help slow the progression of lung function decline, reduce the likelihood of acute flare-ups, and support quality of life over time. 

Managing side effects is a common concern for many people taking antifibrotic therapy. As discussed in the webinar, side effects are relatively common, but many people find they can be managed with practical strategies and support from their healthcare team. Common side effects include diarrhoea, nausea, vomiting, indigestion, reduced appetite, fatigue, and changes in liver function tests. People taking pirfenidone may also experience greater sensitivity to sunlight, which can increase the risk of sun-related skin reactions. 

The webinar explores a range of approaches that some people find helpful when managing diarrhoea, including taking medication with a substantial meal, keeping up fluid intake, and discussing over-the-counter options such with their pharmacist or healthcare team. Some people also find that adjusting certain foods, particularly high-fat or spicy meals, may help. An emerging option discussed during the session was carob powder, which has shown potential in helping some people manage nintedanib-related diarrhoea. 

For nausea or reduced appetite, strategies such as taking medication with food and water, eating smaller meals more frequently, or trying ginger-based products may be worth discussing with a healthcare professional. 

The webinar also highlighted the value of regular monitoring, including blood tests, and discussed how dose adjustments or temporary treatment breaks are sometimes used to help balance treatment benefits and side effects. 

Importantly, patients are encouraged to communicate openly with their healthcare team. Early reporting of side effects can help keep symptoms under control and improve the chances of staying on treatment long enough to gain the full benefits of antifibrotic therapy for pulmonary fibrosis. 

This webinar was produced in collaboration with